08:00 , Feb 12, 2007 |  BC Week In Review  |  Company News

Algynomics, Orthogen deal

The companies will jointly conduct clinical studies in Germany to identify genetic markers that predict patient response to treatments for orthopedic and rheumatologic diseases, including Orthogen's Orthokine , an injection of autologous interleukin-1 (IL-1) receptor...